Amiselimod

Drug Profile

Amiselimod

Alternative Names: MT-1303

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Propylene glycols; Small molecules
  • Mechanism of Action Immunosuppressants; Sphingosine-1-phosphate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Multiple sclerosis; Plaque psoriasis
  • Phase I Autoimmune disorders; Inflammation; Inflammatory bowel diseases; Systemic lupus erythematosus

Most Recent Events

  • 01 Aug 2017 Mitsubishi Tanabe Pharma completes a phase II extension trial in Crohn's disease in Czech Republic, Hungary, Italy, the Netherlands, Poland, Slovakia, France, Germany, Israel, Japan, Ukraine (NCT02389790)
  • 01 May 2017 Mitsubishi Tanabe Pharma completes a phase I trial in Systemic lupus erythematosus (Combination therapy) in Japan (PO) (NCT02307643)
  • 27 Jan 2017 Mitsubishi Tanabe Pharma terminates licence agreement with Biogen for amiselimod worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top